Bayer Buys China’s Dihon to Gain OTC and Herbal Therapies

Bayer AG agreed to buy Dihon Pharmaceutical Group Co. to gain Chinese over-the-counter products and traditional herbal treatments as drug companies expand in Asia.

“This acquisition moves us into a leading position amongst multinationals in the OTC industry in China,” Marijn Dekkers, chief executive officer of the German drugmaker, said today in a statement. “It also brings a portfolio of well-known consumer brands, which will allow us to provide consumers with an even broader range of self-care options.”